Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GB-AOS5
- Development stage
- Preclinical
- Lead developer
- GlycosBio
- Modality
- Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Vaginal
01
Overview
GB-AOS5 is a preclinical-stage therapeutic candidate being developed by GlycosBio for the treatment of post-menopausal vaginal dryness. It utilizes the company's proprietary Activated Oil System (AOS), a lipid-based delivery platform designed to enhance the stability and efficacy of bioactive lipids. The AOS technology aims to provide a non-hormonal alternative for managing symptoms of vulvovaginal atrophy by restoring the natural lipid barrier and improving tissue hydration. As of 2024, the program is in preclinical development, with the sponsor indicating it is approaching clinical stages.
Beyond the preview
Go deeper on GB-AOS5.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GB-AOS5.